Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totaling 8,252 shares, an increase of 77.0% from the June 15th total of 4,661 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.
Innate Pharma Stock Performance
OTCMKTS:IPHYF opened at $1.65 on Friday. The stock has a fifty day moving average price of $1.75 and a 200 day moving average price of $1.85. Innate Pharma has a 12-month low of $1.37 and a 12-month high of $2.25.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
See Also
- Five stocks we like better than Innate Pharma
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
